Semaglutide 5 mg

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist extensively utilized in research focused on metabolic regulation, glycemic control, and obesity management. By mimicking endogenous GLP-1 activity, semaglutide stimulates insulin secretion, suppresses glucagon release, and delays gastric emptying, contributing to improved glucose homeostasis and weight reduction. Semaglutide’s extended half-life allows for once-weekly subcutaneous administration, enhancing compliance in long-term experimental studies. Preclinical and clinical data have demonstrated significant reductions in body weight and favorable effects on cardiovascular risk markers, making semaglutide a key agent in research investigating metabolic syndrome and type 2 diabetes. Ongoing studies continue to explore its broader therapeutic potential in appetite regulation and cardiometabolic health.

This product is intended solely for laboratory research use and is not approved for human or veterinary applications, diagnostic procedures, therapeutic uses, or consumption. All products are sold under the condition that they will be handled exclusively by qualified individuals familiar with their use and potential risks. Any application of this material in humans or animals for therapeutic or diagnostic purposes must comply with the regulations established in 21 CFR 312 and 21 CFR 600.